334 related articles for article (PubMed ID: 26391357)
21. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
22. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.
Speakman M; Kirby R; Doyle S; Ioannou C
BJU Int; 2015 Apr; 115(4):508-19. PubMed ID: 24656222
[TBL] [Abstract][Full Text] [Related]
23. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
24. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
25. Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008.
Egan KB; Suh M; Rosen RC; Burnett AL; Ni X; Wong DG; McVary KT
Int J Clin Pract; 2015 Nov; 69(11):1316-25. PubMed ID: 26215544
[TBL] [Abstract][Full Text] [Related]
26. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.
Zhang LT; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
Clin Interv Aging; 2015; 10():277-86. PubMed ID: 25653511
[TBL] [Abstract][Full Text] [Related]
27. Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Barkin J; Diles D; Franks B; Berner T
Can J Urol; 2015 Aug; 22(4):7914-23. PubMed ID: 26267031
[TBL] [Abstract][Full Text] [Related]
28. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Nickel JC; Jick SS
Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
[TBL] [Abstract][Full Text] [Related]
29. Benign Prostatic Hyperplasia - An economic assessment of fixed combination therapy based on a literature review.
Messina R; Mirone V
Arch Ital Urol Androl; 2015 Sep; 87(3):185-9. PubMed ID: 26428637
[TBL] [Abstract][Full Text] [Related]
30. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
[TBL] [Abstract][Full Text] [Related]
31. Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
.
Eisen C; Lulic Z; Palacios-Moreno JM; Adalig B; Hennig M; Cortes V; Gilg F; Kostev K
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):37-49. PubMed ID: 31670653
[TBL] [Abstract][Full Text] [Related]
32. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine.
Ooi SL; Pak SC
J Altern Complement Med; 2017 Aug; 23(8):599-606. PubMed ID: 28436684
[TBL] [Abstract][Full Text] [Related]
33. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project.
Verhamme KM; Dieleman JP; Bleumink GS; Bosch JL; Stricker BH; Sturkenboom MC
Eur Urol; 2003 Nov; 44(5):539-45. PubMed ID: 14572751
[TBL] [Abstract][Full Text] [Related]
34. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.
Gravas S; Oelke M
World J Urol; 2010 Feb; 28(1):9-15. PubMed ID: 19956956
[TBL] [Abstract][Full Text] [Related]
35. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
36. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
37. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
Vlachopoulos C; Oelke M; Maggi M; Mulhall JP; Rosenberg MT; Brock GB; Esler A; Büttner H
Int J Clin Pract; 2015 Dec; 69(12):1496-507. PubMed ID: 26299520
[TBL] [Abstract][Full Text] [Related]
38. Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.
Ertel P; Adalig B; Demircan I; Lartey B; Manyak MJ
Int J Clin Pract; 2016 Oct; 70(10):870-880. PubMed ID: 27774780
[TBL] [Abstract][Full Text] [Related]
39. Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial.
Kramer JJ; Gu L; Moreira D; Andriole G; Freedland SJ; Csizmadi I
Prostate; 2023 Jul; 83(10):990-997. PubMed ID: 37070723
[TBL] [Abstract][Full Text] [Related]
40. Medical therapy for benign prostatic hyperplasia: a review.
Van Asseldonk B; Barkin J; Elterman DS
Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
